CD274 and urogenital neoplasm: In several cases, including advanced urothelial and genitourinary cancers, PD-L1 has become the strongest biomarker to predict the response to checkpoint inhibitors, a class of immunotherapy that blocks inhibitory signals mainly through the inhibition of the binding between PD-1 and PD-L1 or PD-L2 (92–97).